BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 20399883)

  • 21. Human cone photoreceptor dependence on RPE65 isomerase.
    Jacobson SG; Aleman TS; Cideciyan AV; Heon E; Golczak M; Beltran WA; Sumaroka A; Schwartz SB; Roman AJ; Windsor EA; Wilson JM; Aguirre GD; Stone EM; Palczewski K
    Proc Natl Acad Sci U S A; 2007 Sep; 104(38):15123-8. PubMed ID: 17848510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene augmentation trials using the Rpe65-deficient dog: contributions towards development and refinement of human clinical trials.
    Petersen-Jones SM; Annear MJ; Bartoe JT; Mowat FM; Barker SE; Smith AJ; Bainbridge JW; Ali RR
    Adv Exp Med Biol; 2012; 723():177-82. PubMed ID: 22183331
    [No Abstract]   [Full Text] [Related]  

  • 23. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness.
    Acland GM; Aguirre GD; Bennett J; Aleman TS; Cideciyan AV; Bennicelli J; Dejneka NS; Pearce-Kelling SE; Maguire AM; Palczewski K; Hauswirth WW; Jacobson SG
    Mol Ther; 2005 Dec; 12(6):1072-82. PubMed ID: 16226919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retinal disease in Rpe65-deficient mice: comparison to human leber congenital amaurosis due to RPE65 mutations.
    Caruso RC; Aleman TS; Cideciyan AV; Roman AJ; Sumaroka A; Mullins CL; Boye SL; Hauswirth WW; Jacobson SG
    Invest Ophthalmol Vis Sci; 2010 Oct; 51(10):5304-13. PubMed ID: 20484585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The phenotype of Severe Early Childhood Onset Retinal Dystrophy (SECORD) from mutation of RPE65 and differentiation from Leber congenital amaurosis.
    Weleber RG; Michaelides M; Trzupek KM; Stover NB; Stone EM
    Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):292-302. PubMed ID: 20811047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Altered expression of retinal molecular markers in the canine RPE65 model of Leber congenital amaurosis.
    Hernández M; Pearce-Kelling SE; Rodriguez FD; Aguirre GD; Vecino E
    Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6793-802. PubMed ID: 20671290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular anthropology meets genetic medicine to treat blindness in the North African Jewish population: human gene therapy initiated in Israel.
    Banin E; Bandah-Rozenfeld D; Obolensky A; Cideciyan AV; Aleman TS; Marks-Ohana D; Sela M; Boye S; Sumaroka A; Roman AJ; Schwartz SB; Hauswirth WW; Jacobson SG; Hemo I; Sharon D
    Hum Gene Ther; 2010 Dec; 21(12):1749-57. PubMed ID: 20604683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65.
    Georgiadis A; Duran Y; Ribeiro J; Abelleira-Hervas L; Robbie SJ; Sünkel-Laing B; Fourali S; Gonzalez-Cordero A; Cristante E; Michaelides M; Bainbridge JW; Smith AJ; Ali RR
    Gene Ther; 2016 Dec; 23(12):857-862. PubMed ID: 27653967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Term Structural Outcomes of Late-Stage RPE65 Gene Therapy.
    Gardiner KL; Cideciyan AV; Swider M; Dufour VL; Sumaroka A; Komáromy AM; Hauswirth WW; Iwabe S; Jacobson SG; Beltran WA; Aguirre GD
    Mol Ther; 2020 Jan; 28(1):266-278. PubMed ID: 31604676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Which Leber congenital amaurosis patients are eligible for gene therapy trials?
    Drack AV; Johnston R; Stone EM
    J AAPOS; 2009 Oct; 13(5):463-5. PubMed ID: 19840725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene therapy: light is finally in the tunnel.
    Cao H; Molday RS; Hu J
    Protein Cell; 2011 Dec; 2(12):973-89. PubMed ID: 22231356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis.
    Le Meur G; Lebranchu P; Billaud F; Adjali O; Schmitt S; Bézieau S; Péréon Y; Valabregue R; Ivan C; Darmon C; Moullier P; Rolling F; Weber M
    Mol Ther; 2018 Jan; 26(1):256-268. PubMed ID: 29033008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Leber congenital amaurosis/early-onset severe retinal dystrophy: current management and clinical trials.
    Daich Varela M; Cabral de Guimaraes TA; Georgiou M; Michaelides M
    Br J Ophthalmol; 2022 Apr; 106(4):445-451. PubMed ID: 33712480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Light prevents exogenous 11-cis retinal from maintaining cone photoreceptors in chromophore-deficient mice.
    Fan J; Crouch RK; Kono M
    Invest Ophthalmol Vis Sci; 2011 Apr; 52(5):2412-6. PubMed ID: 21228385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year.
    Cideciyan AV; Hauswirth WW; Aleman TS; Kaushal S; Schwartz SB; Boye SL; Windsor EA; Conlon TJ; Sumaroka A; Pang JJ; Roman AJ; Byrne BJ; Jacobson SG
    Hum Gene Ther; 2009 Sep; 20(9):999-1004. PubMed ID: 19583479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inverse correlation between fatty acid transport protein 4 and vision in Leber congenital amaurosis associated with RPE65 mutation.
    Li S; Gordon WC; Bazan NG; Jin M
    Proc Natl Acad Sci U S A; 2020 Dec; 117(50):32114-32123. PubMed ID: 33257550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy.
    Weleber RG; Pennesi ME; Wilson DJ; Kaushal S; Erker LR; Jensen L; McBride MT; Flotte TR; Humphries M; Calcedo R; Hauswirth WW; Chulay JD; Stout JT
    Ophthalmology; 2016 Jul; 123(7):1606-20. PubMed ID: 27102010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term effect of gene therapy on Leber's congenital amaurosis.
    Bainbridge JW; Mehat MS; Sundaram V; Robbie SJ; Barker SE; Ripamonti C; Georgiadis A; Mowat FM; Beattie SG; Gardner PJ; Feathers KL; Luong VA; Yzer S; Balaggan K; Viswanathan A; de Ravel TJ; Casteels I; Holder GE; Tyler N; Fitzke FW; Weleber RG; Nardini M; Moore AT; Thompson DA; Petersen-Jones SM; Michaelides M; van den Born LI; Stockman A; Smith AJ; Rubin G; Ali RR
    N Engl J Med; 2015 May; 372(20):1887-97. PubMed ID: 25938638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.
    Maguire AM; High KA; Auricchio A; Wright JF; Pierce EA; Testa F; Mingozzi F; Bennicelli JL; Ying GS; Rossi S; Fulton A; Marshall KA; Banfi S; Chung DC; Morgan JI; Hauck B; Zelenaia O; Zhu X; Raffini L; Coppieters F; De Baere E; Shindler KS; Volpe NJ; Surace EM; Acerra C; Lyubarsky A; Redmond TM; Stone E; Sun J; McDonnell JW; Leroy BP; Simonelli F; Bennett J
    Lancet; 2009 Nov; 374(9701):1597-605. PubMed ID: 19854499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo base editing rescues cone photoreceptors in a mouse model of early-onset inherited retinal degeneration.
    Choi EH; Suh S; Foik AT; Leinonen H; Newby GA; Gao XD; Banskota S; Hoang T; Du SW; Dong Z; Raguram A; Kohli S; Blackshaw S; Lyon DC; Liu DR; Palczewski K
    Nat Commun; 2022 Apr; 13(1):1830. PubMed ID: 35383196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.